Cargando…

Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells

RRM1—an important DNA replication/repair enzyme—is the primary molecular gemcitabine (GEM) target. High RRM1-expression associates with gemcitabine-resistance in various cancers and RRM1 inhibition may provide novel cancer treatment approaches. Our study elucidates how RRM1 inhibition affects cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xia, Taoka, Rikiya, Liu, Dage, Matsuoka, Yuki, Tohi, Yoichiro, Kakehi, Yoshiyuki, Sugimoto, Mikio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071414/
https://www.ncbi.nlm.nih.gov/pubmed/33921102
http://dx.doi.org/10.3390/ijms22084102
_version_ 1783683698226364416
author Zhang, Xia
Taoka, Rikiya
Liu, Dage
Matsuoka, Yuki
Tohi, Yoichiro
Kakehi, Yoshiyuki
Sugimoto, Mikio
author_facet Zhang, Xia
Taoka, Rikiya
Liu, Dage
Matsuoka, Yuki
Tohi, Yoichiro
Kakehi, Yoshiyuki
Sugimoto, Mikio
author_sort Zhang, Xia
collection PubMed
description RRM1—an important DNA replication/repair enzyme—is the primary molecular gemcitabine (GEM) target. High RRM1-expression associates with gemcitabine-resistance in various cancers and RRM1 inhibition may provide novel cancer treatment approaches. Our study elucidates how RRM1 inhibition affects cancer cell proliferation and influences gemcitabine-resistant bladder cancer cells. Of nine bladder cancer cell lines investigated, two RRM1 highly expressed cells, 253J and RT112, were selected for further experimentation. An RRM1-targeting shRNA was cloned into adenoviral vector, Ad-shRRM1. Gene and protein expression were investigated using real-time PCR and western blotting. Cell proliferation rate and chemotherapeutic sensitivity to GEM were assessed by MTT assay. A human tumor xenograft model was prepared by implanting RRM1 highly expressed tumors, derived from RT112 cells, in nude mice. Infection with Ad-shRRM1 effectively downregulated RRM1 expression, significantly inhibiting cell growth in both RRM1 highly expressed tumor cells. In vivo, Ad-shRRM1 treatment had pronounced antitumor effects against RRM1 highly expressed tumor xenografts (p < 0.05). Moreover, combination of Ad-shRRM1 and GEM inhibited cell proliferation in both cell lines significantly more than either treatment individually. Cancer gene therapy using anti-RRM1 shRNA has pronounced antitumor effects against RRM1 highly expressed tumors, and RRM1 inhibition specifically increases bladder cancer cell GEM-sensitivity. Ad-shRRM1/GEM combination therapy may offer new treatment options for patients with GEM-resistant bladder tumors.
format Online
Article
Text
id pubmed-8071414
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80714142021-04-26 Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells Zhang, Xia Taoka, Rikiya Liu, Dage Matsuoka, Yuki Tohi, Yoichiro Kakehi, Yoshiyuki Sugimoto, Mikio Int J Mol Sci Article RRM1—an important DNA replication/repair enzyme—is the primary molecular gemcitabine (GEM) target. High RRM1-expression associates with gemcitabine-resistance in various cancers and RRM1 inhibition may provide novel cancer treatment approaches. Our study elucidates how RRM1 inhibition affects cancer cell proliferation and influences gemcitabine-resistant bladder cancer cells. Of nine bladder cancer cell lines investigated, two RRM1 highly expressed cells, 253J and RT112, were selected for further experimentation. An RRM1-targeting shRNA was cloned into adenoviral vector, Ad-shRRM1. Gene and protein expression were investigated using real-time PCR and western blotting. Cell proliferation rate and chemotherapeutic sensitivity to GEM were assessed by MTT assay. A human tumor xenograft model was prepared by implanting RRM1 highly expressed tumors, derived from RT112 cells, in nude mice. Infection with Ad-shRRM1 effectively downregulated RRM1 expression, significantly inhibiting cell growth in both RRM1 highly expressed tumor cells. In vivo, Ad-shRRM1 treatment had pronounced antitumor effects against RRM1 highly expressed tumor xenografts (p < 0.05). Moreover, combination of Ad-shRRM1 and GEM inhibited cell proliferation in both cell lines significantly more than either treatment individually. Cancer gene therapy using anti-RRM1 shRNA has pronounced antitumor effects against RRM1 highly expressed tumors, and RRM1 inhibition specifically increases bladder cancer cell GEM-sensitivity. Ad-shRRM1/GEM combination therapy may offer new treatment options for patients with GEM-resistant bladder tumors. MDPI 2021-04-15 /pmc/articles/PMC8071414/ /pubmed/33921102 http://dx.doi.org/10.3390/ijms22084102 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Zhang, Xia
Taoka, Rikiya
Liu, Dage
Matsuoka, Yuki
Tohi, Yoichiro
Kakehi, Yoshiyuki
Sugimoto, Mikio
Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells
title Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells
title_full Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells
title_fullStr Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells
title_full_unstemmed Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells
title_short Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells
title_sort knockdown of rrm1 with adenoviral shrna vectors to inhibit tumor cell viability and increase chemotherapeutic sensitivity to gemcitabine in bladder cancer cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071414/
https://www.ncbi.nlm.nih.gov/pubmed/33921102
http://dx.doi.org/10.3390/ijms22084102
work_keys_str_mv AT zhangxia knockdownofrrm1withadenoviralshrnavectorstoinhibittumorcellviabilityandincreasechemotherapeuticsensitivitytogemcitabineinbladdercancercells
AT taokarikiya knockdownofrrm1withadenoviralshrnavectorstoinhibittumorcellviabilityandincreasechemotherapeuticsensitivitytogemcitabineinbladdercancercells
AT liudage knockdownofrrm1withadenoviralshrnavectorstoinhibittumorcellviabilityandincreasechemotherapeuticsensitivitytogemcitabineinbladdercancercells
AT matsuokayuki knockdownofrrm1withadenoviralshrnavectorstoinhibittumorcellviabilityandincreasechemotherapeuticsensitivitytogemcitabineinbladdercancercells
AT tohiyoichiro knockdownofrrm1withadenoviralshrnavectorstoinhibittumorcellviabilityandincreasechemotherapeuticsensitivitytogemcitabineinbladdercancercells
AT kakehiyoshiyuki knockdownofrrm1withadenoviralshrnavectorstoinhibittumorcellviabilityandincreasechemotherapeuticsensitivitytogemcitabineinbladdercancercells
AT sugimotomikio knockdownofrrm1withadenoviralshrnavectorstoinhibittumorcellviabilityandincreasechemotherapeuticsensitivitytogemcitabineinbladdercancercells